The Faecal Immunochemical Test (FIT) is now an established bowel cancer test. This diagnostic assay identifies the presence of hidden blood in the stool, known as faecal occult blood (FOB), which can be an early sign of colorectal cancer. FIT uses antibodies specific to human haemoglobin so is more accurate and sensitive, provides a quantitative measurement, and gives fewer false positive results than other tests.
Read MoreFor the National Bowel Cancer Screening programmes FIT is bringing many advantages. Easier sampling methods are more acceptable to people invited for screening, which promotes greater uptake. Non-subjective, automated processing of samples advances laboratory efficiencies, improving standardisation and quality control. FIT is more sensitive and can detect cancers more reliably and at an earlier stage than previous methods used.
Read MoreNICE Guidance DG56 recommends “Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care”. NICE concludes that a cut-off of 10 μg of Hb/ g faeces in a FIT has a high negative predictive value for colorectal cancer and other serious bowel diseases, therefore, FIT should be used to triage for referral to secondary care, people whose symptoms suggest colorectal cancer, but in whom a definitive diagnosis of cancer is unlikely.
Read MoreThe HM-JACKarc system provides automated, rapid and consistent, high throughput Faecal
Faecal Immunochemical Testing – Past, Present and Future At the ACB
On Thursday 2nd December 2021, at the Annual MediWales conference in
The HM-JACKarc FIT system employs an innovative sample collection device that
HM-JACKarc Automated FIT Test
Innovative FIT Sample Collection Device
Sensitive Latex Turbidimetry
Customised FIT Test Instructions for Use
Complete Patient Packs
NICE DG56 vs. NICE DG30 March 21, 2024
A New Portal to Ef-FIT-ciency June 16, 2023
Partnership with the NHS Award Winners! December 7, 2021
